Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) and Palisade Bio (NASDAQ:PALI – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.
Volatility & Risk
Genocea Biosciences has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Genocea Biosciences and Palisade Bio, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Genocea Biosciences and Palisade Bio’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Genocea Biosciences||$1.64 million||0.00||-$33.20 million||N/A||N/A|
|Palisade Bio||$10,000.00||971.50||-$14.26 million||N/A||N/A|
Palisade Bio has lower revenue, but higher earnings than Genocea Biosciences.
This table compares Genocea Biosciences and Palisade Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 1.3% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genocea Biosciences beats Palisade Bio on 6 of the 8 factors compared between the two stocks.
About Genocea Biosciences
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
About Palisade Bio
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.